PHILADELPHIA, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced publication of an article entitled "Emergence of a novel drug resistant H7N9 influenza virus: Evidence based clinical potential of a natural IFN-alpha for infection control and treatment" in Expert Review of Anti-infective Therapy early online edition pages 1-5, 2014 . H7N9 is a recently identified virus associated with high mortality in humans with the potential to emerge as an agent for a global pandemic. New cases of H7N9 have been very recently reported in China, Hong Kong and Taiwan. In vitro tests reported in the new article demonstrated that both oseltamivir (Tamiflu ®) and Alferon N have significant inhibitory effect on a neuraminidase inhibitor sensitive H7N9 influenza virus. In contrast, Alferon N, but not Tamiflu ®, had an inhibitory effect on the neuraminidase resistant Shanghai/1/H7N9 virus.
Hemispherx Biopharma Reports Evidence Based Clinical Potential Of A Natural Interferon (IFN) -- Alpha For Infection Control And Treatment Of Drug Resistant H7N9 Influenza Virus
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.